Gland Pharma Limited — Q4 FY26
Gland Pharma delivered a strong Q4 FY26 with consolidated revenue of ₹1,742.8 crore (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDMO growth (46%...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Synexi annual revenue baseline of €200 million
Synexi's Q3 revenue of €50 million sets a baseline for annualized revenue of ~€200 million, with potential quarterly fluctuations.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1